Provided by Tiger Trade Technology Pte. Ltd.

Pasithea Therapeutics Corp.

0.5300
-0.0100-1.85%
Post-market: 0.53000.00000.00%17:25 EDT
Volume:141.09K
Turnover:74.97K
Market Cap:17.71M
PE:-0.36
High:0.5515
Open:0.5310
Low:0.5202
Close:0.5400
52wk High:2.06
52wk Low:0.2810
Shares:33.41M
Float Shares:10.20M
Volume Ratio:0.66
T/O Rate:1.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4820
EPS(LYR):-2.9100
ROE:-65.49%
ROA:-36.00%
PB:0.36
PE(LYR):-0.18

Loading ...

Pasithea Therapeutics Corp reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
May 16

Pasithea net loss narrows 19.5% to $2.87 million in Q1 2026

Reuters
·
May 16

Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
May 12

Pasithea Therapeutics files Form 3 for Chief Medical Officer Kartik Krishnan

Reuters
·
May 06

Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives

TIPRANKS
·
May 05

Pasithea Therapeutics names Kartik Krishnan chief medical officer

Reuters
·
May 04

Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 21

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

GlobeNewswire
·
Apr 20

Pasithea Therapeutics files Form 3 beneficial ownership statement for Coastlands Capital LP

Reuters
·
Apr 18

Pasithea Therapeutics Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Apr 03

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

GlobeNewswire
·
Apr 01

Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
Apr 01

Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock

Simply Wall St.
·
Mar 25

Pasithea Therapeutics Corp expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
Mar 21